Retatrutide Explained: The Triple Agonist Peptide Changing Weight Loss and Metabolism
About this episode
In this episode of The Peptide Effect Podcast, we break down Retatrutide, one of the most talked-about new research compounds in the weight loss and metabolic health world. We explain what Retatrutide is, why it’s called a “triple agonist,” and how it differs from Semaglutide and Tirzepatide. You’ll learn how it works on GLP-1, GIP, and glucagon receptors, what benefits researchers are seeing so far, and what side effects and risks people need to be aware of. If you’re curious about the future of fat loss peptides, insulin resistance support, and next-level metabolic compounds, this episode is a must-listen.
Disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider before using any peptide or research compound.
Get every episode summarized
Each time The Peptide Effect publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Peptide Effect
The Hidden GLP-1 Switch: How These Drugs May Reprogram Pancreatic Cells
The Peptide Effect
The Science of Peptide-Based Myostatin Inhibitors: Can We Unlock More Muscle?
The Peptide Effect
Apolipoprotein-Targeting Peptides: The Future of Cholesterol, Brain Health, and...
The Peptide Effect
Border Seizures and the Peptide Market: What’s Happening to Supply, Pricing, and...
The Peptide Effect